Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• Colorectal carcinoma recurrence poses a significant clinical challenge.
• Accurate detection of recurrent colorectal cancer is crucial for timely and effective patient management.
• Conventional imaging modalities like computed tomography (CT) have limitations in diagnosing recurrence.

Purpose of the Study:

• To evaluate the diagnostic accuracy of whole-body 2-[F-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) for recurrent colorectal carcinoma.
• To compare the performance of FDG-PET with conventional CT in detecting colorectal cancer recurrence.
• To assess the clinical utility of FDG-PET in staging patients with suspected recurrent disease.

Main Methods:

• Forty patients with suspected recurrent colorectal carcinoma underwent whole-body FDG-PET.
• Patient selection was based on elevated carcinoembryonic antigen (CEA) levels or equivocal CT findings.
• FDG-PET results were compared with CT findings and confirmed by histopathology or clinical follow-up.

Main Results:

• FDG-PET demonstrated higher positive (96-98%) and negative (83-93%) predictive values compared to CT (75-88% and 67-71%).
• The area under the receiver operating characteristic curve for FDG-PET (0.96) was significantly greater than for CT (0.77).
• Lesions with a maximum standardized uptake value (SUVmax) above 5.0 were more likely to be malignant.

Conclusions:

• Whole-body FDG-PET is a more accurate imaging modality than conventional CT for diagnosing recurrent colorectal carcinoma.
• FDG-PET provides superior sensitivity and specificity in detecting disease recurrence.
• FDG-PET should be considered a valuable tool in the staging of patients with suspected recurrent colorectal cancer.